ZA200400521B - Antibodies to OPGL. - Google Patents

Antibodies to OPGL.

Info

Publication number: ZA200400521B
Authority: ZA; South Africa
Prior art keywords: opgl; antibodies
Prior art date: 2001-06-26

Application number

ZA200400521A

Other languages

English (en)

Inventor

William J Boyle

Francis H Martin

Jose R Corvalan

Geoffrey C Davis

Original Assignee

Abgenic Inc

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-26

Filing date

2004-01-23

Publication date

2005-07-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200400521(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-23 Application filed by Abgenic Inc, Amgen Inc filed Critical Abgenic Inc

2005-07-27 Publication of ZA200400521B publication Critical patent/ZA200400521B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Mycology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

ZA200400521A 2001-06-26 2004-01-23 Antibodies to OPGL. ZA200400521B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30117201P	2001-06-26	2001-06-26

Publications (1)

Publication Number	Publication Date
ZA200400521B true ZA200400521B (en)	2005-07-27

Family

ID=23162250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200400521A ZA200400521B (en)	2001-06-26	2004-01-23	Antibodies to OPGL.

Country Status (34)

Country	Link
US (8)	US7364736B2 (ja)
EP (5)	EP2270052B8 (ja)
JP (13)	JP4212470B2 (ja)
KR (2)	KR101038585B1 (ja)
CN (2)	CN103232539B (ja)
AR (1)	AR034637A1 (ja)
AT (1)	ATE464068T1 (ja)
AU (2)	AU2002320157C1 (ja)
BR (1)	BRPI0210579B8 (ja)
CA (1)	CA2451955C (ja)
CY (5)	CY1110196T1 (ja)
DE (2)	DE122010000047I1 (ja)
DK (4)	DK2087908T3 (ja)
EA (1)	EA021242B9 (ja)
ES (5)	ES2706902T3 (ja)
FR (1)	FR10C0050I2 (ja)
HK (1)	HK1187932A1 (ja)
IL (3)	IL159512A0 (ja)
LU (1)	LU91757I2 (ja)
ME (2)	MEP32608A (ja)
MX (1)	MXPA04000134A (ja)
MY (1)	MY143582A (ja)
NO (5)	NO345566B1 (ja)
NZ (4)	NZ530765A (ja)
PH (2)	PH12012502439A1 (ja)
PL (1)	PL222211B1 (ja)
PT (4)	PT2295081T (ja)
RS (1)	RS54274B1 (ja)
SG (3)	SG2011076551A (ja)
TR (3)	TR201809678T4 (ja)
TW (2)	TWI276443B (ja)
WO (1)	WO2003002713A2 (ja)
YU (1)	YU103003A (ja)
ZA (1)	ZA200400521B (ja)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en) *	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
EP2371962A3 (en)	1996-12-23	2011-12-21	Immunex Corporation	Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
ES2263204T5 (es)	1997-04-15	2013-10-14	Daiichi Sankyo Company, Limited	Nueva proteína y proceso para producir la misma
CN1264427A (zh) *	1997-04-16	2000-08-23	安姆根有限公司	osteoprotegerin结合蛋白和受体
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
AU762574B2 (en)	1998-05-14	2003-06-26	Immunex Corporation	Method of inhibiting osteoclast activity
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
MXPA03002443A (es)	2000-09-22	2004-12-06	Immunex Corp	Ensayos de clasificacion para agonistas o antagonistas del activador receptor de nf-kb.
IL156661A0 (en) *	2001-01-05	2004-01-04	Pfizer	Antibodies to insulin-like growth factor i receptor
JP4212470B2 (ja) *	2001-06-26	2009-01-21	アムジェンフレモントインク．	Ｏｐｇｌへの抗体
AU2003243139B2 (en) *	2002-04-05	2007-06-21	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
SI1561756T1 (sl)	2002-09-11	2016-02-29	Chugai Seiyaku Kabushiki Kaisha	Postopek čiščenja proteinov
EP1479695B1 (en) *	2003-05-14	2010-02-17	Kenta Biotech AG	Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
BR0318454A (pt)	2003-08-08	2006-09-12	Abgenix Inc	anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
ES2285543T3 (es) *	2003-11-05	2007-11-16	Ares Trading S.A.	Procedimiento para la purificacion de la proteina de union a il-18.
TWI359026B (en) *	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
JP4840939B2 (ja)	2004-08-04	2011-12-21	アムジェンインコーポレイテッド	Ｄｋｋ−１に対する抗体
US20060115901A1 (en) *	2004-10-22	2006-06-01	Bahram Valamehr	Method and media for single cell serum-free culture of CHO cells
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
KR20080006601A (ko) *	2005-04-11	2008-01-16	메다렉스, 인코포레이티드	단백질 정제 방법
AU2015242973C1 (en) *	2005-06-14	2018-07-05	Amgen Inc.	Self-buffering protein formulations
CN101217979A (zh) *	2005-06-14	2008-07-09	安姆根有限公司	自缓冲蛋白制剂
CA2615731A1 (en) *	2005-07-29	2007-02-08	Amgen Inc.	Formulations that inhibit protein aggregation
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en)	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2007093042A1 (en)	2006-02-13	2007-08-23	Alethia Biotherapeutics Inc.	Polynucleotides and polypeptide sequences involved in the process of bone remodeling
CA2650676C (en)	2006-04-28	2016-03-22	Kyoritsu Seiyaku Corporation	Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof
FI2061803T4 (fi)	2006-08-28	2023-03-14		Process for the purification of fc-containing proteins
US20100260766A1 (en) *	2007-03-22	2010-10-14	Arvind Srivastava	Stable antibody formulations
ES2663512T3 (es)	2007-05-24	2018-04-13	Ablynx N.V.	Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos
ES2650224T3 (es)	2007-08-21	2018-01-17	Amgen, Inc.	Proteínas de unión al antígeno C-FMS humano
JP5963341B2 (ja) *	2007-09-14	2016-08-10	アムジエン・インコーポレーテツド	均質な抗体集団
AU2008304111B2 (en)	2007-09-27	2014-04-24	Amgen Inc.	Pharmaceutical formulations
ES2540733T3 (es)	2007-10-11	2015-07-13	Daiichi Sankyo Company, Limited	Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
US8796206B2 (en)	2007-11-15	2014-08-05	Amgen Inc.	Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
EP2250251B1 (en)	2008-01-09	2017-11-22	Sartorius Stedim Cellca GmbH	Improved culture media additive and process for using it
US20110060290A1 (en) *	2008-02-07	2011-03-10	Amgen Inc.	Stabilized protein compositions
AR073072A1 (es) *	2008-08-19	2010-10-13	Regeneron Pharma	Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
EP2401297A1 (en)	2009-02-24	2012-01-04	Glaxo Group Limited	Antigen-binding constructs
CA2753287A1 (en)	2009-02-24	2010-09-02	Glaxo Group Limited	Antigen-binding constructs
WO2010097394A1 (en)	2009-02-24	2010-09-02	Glaxo Group Limited	Multivalent and/or multispecific rankl-binding constructs
US8575316B2 (en)	2009-04-09	2013-11-05	Daiichi Sankyo Company, Limited	Anti-Siglec-15 antibody
US9662271B2 (en)	2009-10-23	2017-05-30	Amgen Inc.	Vial adapter and system
HUE059169T2 (hu)	2010-02-01	2022-10-28	Rebiotix Inc	Baktériumterápia Clostridium difficile colitis számára
HUE026173T2 (en)	2010-06-07	2016-05-30	Amgen Inc	pharmaceutical Pump
JP5699030B2 (ja) *	2010-07-05	2015-04-08	Ａｘｉｓ株式会社	エタネルセプトを含む線維筋痛症の治療剤
TW201219568A (en)	2010-10-05	2012-05-16	Daiichi Sankyo Co Ltd	Antibody targeting osteoclast-related protein Siglec-15
ES2562274T3 (es)	2010-10-06	2016-03-03	Fundació Institut De Recerca Biomèdica (Irb Barcelona)	Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
CA2831100C (en)	2011-03-31	2020-02-18	Mark Dominis Holt	Vial adapter and system
JP6038884B2 (ja)	2011-04-20	2016-12-07	アムゲン・インコーポレーテッド	自動式注射装置
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN108329391A (zh)	2011-05-27	2018-07-27	埃博灵克斯股份有限公司	使用rankl结合肽抑制骨质吸收
LT3045187T (lt)	2011-10-14	2019-07-10	Amgen Inc.	Injekcijų įrenginys ir surinkimo būdas
CN104023743B (zh)	2011-10-25	2017-05-03	普罗西纳治疗有限公司	抗体制剂和方法
US9353153B2 (en)	2012-02-09	2016-05-31	Riken	Cyclic RNA and protein production method
IN2014DN08215A (ja)	2012-03-30	2015-05-15	Daiichi Sankyo Companyltd
EP2650682A1 (en)	2012-04-09	2013-10-16	Fundació Privada Institut de Recerca Biomèdica	Method for the prognosis and treatment of cancer metastasis
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
EP2856159A4 (en) *	2012-06-01	2016-04-13	Momenta Pharmaceuticals Inc	METHODS RELATING TO DENOSUMAB
BR112014030750A2 (pt)	2012-06-06	2017-08-22	Inst Catalana Recerca Estudis Avancats	Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
EP2875051B1 (en)	2012-07-19	2019-02-20	Daiichi Sankyo Company, Limited	Anti-siglec-15 antibodies
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
WO2014035475A1 (en)	2012-09-02	2014-03-06	Abbvie Inc.	Methods to control protein heterogeneity
SG10201705668XA (en)	2012-09-07	2017-08-30	Coherus Biosciences Inc	Stable aqueous formulations of adalimumab
BR112015008255B1 (pt)	2012-10-12	2023-02-28	Inbiomotion S.L	Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte
US10119171B2 (en)	2012-10-12	2018-11-06	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2780395T3 (es)	2012-11-21	2020-08-25	Amgen Inc	Dispositivo de administración de fármacos
DK2948553T3 (da)	2013-01-25	2020-06-29	Baylor College Medicine	Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi
CA2905010A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2904661C (en)	2013-03-15	2022-03-15	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
WO2014184679A2 (en)	2013-03-15	2014-11-20	Inbiomotion S.L.	Method for the prognosis and treatment of renal cell carcinoma metastasis
KR102295834B1 (ko)	2013-03-15	2021-08-30	암젠 인크	인체 윤곽 적응성을 가진 자기 주사기 장치
CA2904725C (en)	2013-03-15	2022-04-12	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
KR20150122731A (ko)	2013-03-15	2015-11-02	펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나)	암 전이의 예후 및 치료 방법
WO2014149067A1 (en)	2013-03-15	2014-09-25	Momenta Pharmaceuticals, Inc.	Methods related to ctla4-fc fusion proteins
EP3831427A1 (en)	2013-03-22	2021-06-09	Amgen Inc.	Injector and method of assembly
WO2014186310A1 (en)	2013-05-13	2014-11-20	Momenta Pharmaceuticals, Inc.	Methods for the treatment of neurodegeneration
US9481901B2 (en)	2013-05-30	2016-11-01	Amgen Inc.	Methods for increasing mannose content of recombinant proteins
US10383901B2 (en)	2013-06-05	2019-08-20	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9675648B2 (en)	2013-06-05	2017-06-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en)	2013-06-05	2017-07-04	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en)	2013-06-05	2017-10-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN105555291B (zh)	2013-08-07	2021-08-24	助育公司	用于治疗雄性不育症的抗体、化合物及其衍生物
TW201605896A (zh)	2013-08-30	2016-02-16	安美基股份有限公司	Gitr抗原結合蛋白
WO2015047994A2 (en) *	2013-09-24	2015-04-02	The Board Of Regentsl Of The University Of Texas System	A novel hormone that promotes bone resorption and uses thereof
EP3052640A2 (en)	2013-10-04	2016-08-10	AbbVie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
BR112016007864A2 (pt)	2013-10-09	2017-12-05	Fundacio Inst De Recerca Biomedica Irb Barcelona	método para a prognose e tratamento de metástase de câncer
WO2015057622A1 (en)	2013-10-16	2015-04-23	Momenta Pharmaceuticals, Inc.	Sialylated glycoproteins
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
EP3789064B1 (en)	2013-10-24	2024-11-27	Amgen Inc.	Injector and method of assembly
CA2926110C (en)	2013-10-24	2023-05-23	Amgen Inc.	Drug delivery system with temperature-sensitive control
WO2015073884A2 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
ES2729797T3 (es) *	2013-12-20	2019-11-06	Dev Ct Biotechnology	Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
CN103965357B (zh) *	2013-12-31	2016-08-17	嘉和生物药业有限公司	一种抗人rankl抗体
WO2015119906A1 (en)	2014-02-05	2015-08-13	Amgen Inc.	Drug delivery system with electromagnetic field generator
ES2784749T3 (es)	2014-03-10	2020-09-30	Richter Gedeon Nyrt	Purificación de inmunoglobulina con el uso de etapas de limpieza previa
CA3193070A1 (en)	2014-05-07	2015-11-12	Amgen Inc.	Autoinjector with shock reducing elements
JP6742248B2 (ja)	2014-06-03	2020-08-19	アムジエン・インコーポレーテツド	薬物送達装置の使用者を支援するための装置及び方法
ES2980493T3 (es) *	2014-06-04	2024-10-01	Amgen Inc	Métodos de recolección en cultivos de células de mamífero
MX2017004836A (es)	2014-10-14	2017-07-20	Amgen Inc	Dispositivo de inyeccion de farmaco con indicadores visuales y audibles.
CN107001480B (zh)	2014-12-11	2021-12-03	生物运动有限公司	用于人c-maf的结合成员
WO2016100055A1 (en)	2014-12-19	2016-06-23	Amgen Inc.	Drug delivery device with live button or user interface field
US10799630B2 (en)	2014-12-19	2020-10-13	Amgen Inc.	Drug delivery device with proximity sensor
US10583245B2 (en)	2015-02-17	2020-03-10	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
US10328123B2 (en)	2015-02-25	2019-06-25	Saint Louis University	Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis
US10745461B2 (en)	2015-02-25	2020-08-18	Saint Louis University	Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis
US10111928B1 (en) *	2015-02-25	2018-10-30	Saint Louis University	Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta
EP3981450A1 (en)	2015-02-27	2022-04-13	Amgen, Inc	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
MX2017013802A (es)	2015-04-29	2018-08-15	Radius Pharmaceuticals Inc	Métodos para tratar el cáncer.
US10799539B2 (en)	2015-06-09	2020-10-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
WO2016201114A1 (en)	2015-06-09	2016-12-15	Rebiotix, Inc.	Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10905726B2 (en)	2015-06-09	2021-02-02	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
HU231463B1 (hu)	2015-08-04	2024-01-28	Richter Gedeon Nyrt.	Módszer rekombináns proteinek galaktóz tartalmának növelésére
EP3334747B1 (en)	2015-08-13	2023-09-27	Amgen Inc.	Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
ES2755717T3 (es)	2015-12-09	2020-04-23	Amgen Inc	Autoinyector con tapa de señalización
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
MA43814A (fr)	2016-03-08	2018-11-28	Janssen Biotech Inc	Anticorps anti-gitr, méthodes et utilisations
WO2017160799A1 (en)	2016-03-15	2017-09-21	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
WO2017192287A1 (en)	2016-05-02	2017-11-09	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es)	2016-05-13	2024-02-28	Amgen Inc	Conjunto de cubierta protectora de vial
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
WO2017203468A1 (en)	2016-05-25	2017-11-30	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-maf status
WO2017209899A1 (en)	2016-06-03	2017-12-07	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en)	2016-07-01	2019-05-08	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
WO2018075818A1 (en)	2016-10-21	2018-04-26	Amgen Inc.	Pharmaceutical formulations and methods of making the same
WO2018081234A1 (en)	2016-10-25	2018-05-03	Amgen Inc.	On-body injector
KR102322802B1 (ko)	2017-01-05	2021-11-04	래디어스 파마슈티컬스, 인코포레이티드	Rad1901-2hcl의 다형 형태
CA3049780A1 (en)	2017-01-17	2018-07-26	Amgen Inc.	Injection devices and related methods of use and assembly
MX2019009625A (es)	2017-02-17	2019-10-09	Amgen Inc	Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
JP7280189B2 (ja)	2017-02-17	2023-05-23	アムジエン・インコーポレーテツド	薬物送達装置用の挿入機構
JP2020508803A (ja)	2017-03-06	2020-03-26	アムジエン・インコーポレーテツド	作動防止特徴部を備える薬物送達デバイス
US11571511B2 (en)	2017-03-07	2023-02-07	Amgen Inc.	Insertion mechanism and method of inserting a needle of a drug delivery device
WO2018165499A1 (en)	2017-03-09	2018-09-13	Amgen Inc.	Insertion mechanism for drug delivery device
EA202190785A1 (ru)	2017-03-28	2021-10-29	Эмджен Инк.	Система и способ сборки штока поршня и шприца
JOP20190255A1 (ar)	2017-04-28	2019-10-27	Amgen Inc	صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
MX2019013072A (es)	2017-05-02	2019-12-16	Merck Sharp & Dohme	Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3061982A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
WO2018226565A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Torque driven drug delivery device
CA3063920A1 (en)	2017-06-22	2018-12-27	Amgen Inc.	Device activation impact/shock reduction
MX2019015479A (es)	2017-06-23	2020-02-20	Amgen Inc	Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
WO2019014014A1 (en)	2017-07-14	2019-01-17	Amgen Inc.	NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
MA49626A (fr)	2017-07-21	2020-05-27	Amgen Inc	Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49677A (fr)	2017-07-25	2021-04-21	Amgen Inc	Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
US11484648B2 (en)	2017-07-25	2022-11-01	Amgen Inc.	Drug delivery device with container access system and related method of assembly
US20200164155A1 (en)	2017-08-09	2020-05-28	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr)	2017-08-18	2020-06-24	Amgen Inc	Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
EP3691717B1 (en)	2017-10-04	2023-02-08	Amgen Inc.	Flow adapter for drug delivery device
US11813426B2 (en)	2017-10-06	2023-11-14	Amgen Inc.	Drug delivery device including seal member for needle of syringe
EP3694578A1 (en)	2017-10-09	2020-08-19	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
IL273663B1 (en)	2017-11-03	2025-01-01	Amgen Inc	System and methods for disinfecting a drug delivery device
CA3079197A1 (en)	2017-11-06	2019-05-09	Amgen Inc.	Drug delivery device with placement and flow sensing
MA50569A (fr)	2017-11-06	2020-09-16	Amgen Inc	Ensembles de remplissage-finition et procédés associés
CA3079665A1 (en)	2017-11-10	2019-05-16	Amgen Inc.	Plungers for drug delivery devices
CN111278487B (zh)	2017-11-16	2022-06-24	安进公司	用于药物递送装置的门闩锁机构
MA50903A (fr)	2017-11-16	2021-05-12	Amgen Inc	Auto-injecteur avec détection de décrochage et de point d'extrémité
US11654153B2 (en)	2017-11-22	2023-05-23	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-MAF status
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
EP3817821A1 (en)	2018-07-04	2021-05-12	Radius Pharmaceuticals, Inc.	Polymorphic forms of rad 1901-2hcl
WO2020023220A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MA53375A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
MX2021000748A (es)	2018-07-24	2021-03-26	Amgen Inc	Dispositivos de suministro para administrar farmacos.
WO2020028009A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
CA3106452A1 (en)	2018-09-24	2020-04-02	Amgen Inc.	Interventional dosing systems and methods
IL281469B2 (en)	2018-09-28	2024-08-01	Amgen Inc	Muscle wire escapement activation assembly for a drug delivery device
IL281712B1 (en)	2018-10-02	2024-11-01	Amgen Inc	Injection systems for drug delivery with internal force transmission
CA3112214A1 (en)	2018-10-05	2020-04-09	Amgen Inc.	Drug delivery device having dose indicator
CN112789073B (zh)	2018-10-15	2023-09-15	安进公司	具有阻尼机构的药物递送装置
EA202191038A1 (ru)	2018-10-15	2021-07-06	Эмджен Инк.	Способ платформенной сборки для устройства доставки лекарственного средства
CA3113076A1 (en)	2018-11-01	2020-05-07	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
WO2020091956A1 (en)	2018-11-01	2020-05-07	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
HU231514B1 (hu)	2018-11-07	2024-07-28	Richter Gedeon Nyrt.	Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
HU231498B1 (hu)	2019-04-04	2024-05-28	Richter Gedeon Nyrt	Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
AU2020263289A1 (en)	2019-04-24	2021-09-16	Amgen Inc.	Syringe sterilization verification assemblies and methods
CA3132656A1 (en)	2019-04-30	2020-11-05	Instituto De Medicina Molecular Joao Lobo Antunes	Rank pathway inhibitors in combination with cdk inhibitors
JP7608439B2 (ja)	2019-08-23	2025-01-06	アムジエン・インコーポレーテツド	構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
EP4110371A1 (en)	2020-01-24	2023-01-04	Radius Health, Inc.	Methods of stimulating bone growth with abalopartide and denosumab
CN113621060B (zh) *	2020-05-07	2023-07-04	浙江瑞硕生物技术有限公司	一种opg抗体对及其应用
DE112021007405T5 (de)	2021-03-29	2024-01-18	Mitsubishi Electric Corporation	Halbleitereinheit, verfahren zur herstellung einer halbleitereinheit und verfahren zum ersetzen einer halbleitereinheit
AU2022279223A1 (en)	2021-05-21	2023-10-19	Amgen Inc.	Method of optimizing a filling recipe for a drug container
WO2024064878A1 (en)	2022-09-23	2024-03-28	The University Of North Carolina At Chapel Hill	Methods and compositions for the treatment of melanoma
WO2024104409A1 (zh) *	2022-11-16	2024-05-23	苏州盛迪亚生物医药有限公司	一种含抗rankl-ngf双特异性抗体的药物组合物

Family Cites Families (290)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) *	1980-04-11	1982-07-06	President And Fellows Of Harvard College	Mature protein synthesis
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4755465A (en) *	1983-04-25	1988-07-05	Genentech, Inc.	Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4710457A (en) *	1983-06-29	1987-12-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibody for human hematopoietic glycoproteins and method
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4699880A (en)	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US5900400A (en)	1984-12-06	1999-05-04	Amgen Inc.	Serine protease inhibitor analogs
US4760130A (en)	1984-12-06	1988-07-26	Synergen Biologicals, Inc.	Serine protease inhibitors and methods for isolation of same
JPS6291197A (ja)	1985-10-17	1987-04-25	Dainippon Pharmaceut Co Ltd	抗ヒトインタ−ロイキン１抗体，その製法及びその使用法
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4935343A (en)	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
DK590387A (da)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US5359032A (en)	1987-08-26	1994-10-25	Biogen Inc.	Interkeukin-1 inhibitor
IL83878A (en)	1987-09-13	1995-07-31	Yeda Res & Dev	Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en)	1987-09-13	1996-04-30	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising an anticytokine
IL98078A0 (en)	1991-05-07	1992-06-21	Yeda Res & Dev	Pharmaceutical compositions comprising an anticytokyne
US5106627A (en)	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
WO1989004838A1 (en)	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
US5319071A (en)	1987-11-25	1994-06-07	Immunex Corporation	Soluble interleukin-1 receptors
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
US5846534A (en) *	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
US4942184A (en) *	1988-03-07	1990-07-17	The United States Of America As Represented By The Department Of Health And Human Services	Water soluble, antineoplastic derivatives of taxol
GB8807803D0 (en)	1988-03-31	1988-05-05	Glaxo Group Ltd	Biochemical product
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
IL94039A (en)	1989-08-06	2006-09-05	Yeda Res & Dev	Antibodies to tbp - 1 and their use
US5811261A (en)	1988-09-12	1998-09-22	Yeda Research And Development Co. Ltd.	Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en)	1988-09-12	1994-10-25	Yeda Research And Development Co. Ltd.	Antibodies to TNF binding protein I
EP0364778B1 (en)	1988-10-01	1996-03-13	Otsuka Pharmaceutical Co., Ltd.	Antibody against interleukin-1beta
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2238070T3 (es)	1989-04-21	2005-08-16	Amgen Inc.	Receptor del tnf, proteina ligante del tnf y adn codante para estos.
DE3922089A1 (de)	1989-05-09	1990-12-13	Basf Ag	Neue proteine und ihre herstellung
IL107267A (en)	1993-10-12	2009-07-20	Yeda Res & Dev	Ligand to a member of the tnf/ngf receptor family
ATE119942T1 (de)	1989-05-18	1995-04-15	Yeda Res & Dev	Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
WO1990014363A1 (en)	1989-05-19	1990-11-29	Amgen Inc.	Metalloproteinase inhibitor
US5627262A (en)	1989-07-05	1997-05-06	The Board Of Regents Of The University Of Oklahoma	Method and composition for the treatment of septic shock
IL95031A (en)	1989-07-18	2007-03-08	Amgen Inc	A method of producing a recombinant human necrotic factor absorber
CA2485553A1 (en)	1989-09-05	1991-03-21	Immunex Corporation	Tumor necrosis factor - .alpha. and - .beta. receptors
US5395760A (en)	1989-09-05	1995-03-07	Immunex Corporation	DNA encoding tumor necrosis factor-α and -β receptors
DE59010933D1 (de)	1989-09-12	2003-05-08	Hoffmann La Roche	TFN-bindende Proteine
JPH03127800A (ja)	1989-10-13	1991-05-30	Teijin Ltd	腫瘍壊死因子活性抑制物質
ES2103305T3 (es)	1989-11-29	1997-09-16	Amgen Boulder Inc	Produccion de inhibidor de interleuquina-1 humana recombinada.
AU642938B2 (en)	1989-12-13	1993-11-04	Yeda Research And Development Co. Ltd.	Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5136021A (en)	1990-02-27	1992-08-04	Health Research, Inc.	TNF-inhibitory protein and a method of production
AU649245B2 (en)	1990-04-02	1994-05-19	Amgen, Inc.	Methods for treating interleukin-1 mediated diseases
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
AU7683391A (en)	1990-04-27	1991-11-27	Upjohn Company, The	Modified interleukin-1 inhibitors
EP0534978B1 (en)	1990-05-01	1999-03-24	Chiron Corporation	Interleukin-1 antagonist and uses thereof
US5872095A (en)	1990-05-01	1999-02-16	Chiron Corporation	IL-1 receptor antagonists medicaments
US5350683A (en)	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
GB2246569A (en)	1990-06-15	1992-02-05	Charing Cross Sunley Research	Tumour necrosis factor - alpha binding protein
DE59109269D1 (de)	1990-06-28	2005-12-15	Hoechst Ag	Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
WO1992001002A1 (fr)	1990-07-11	1992-01-23	Teijin Limited	Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
US5420154A (en)	1990-08-03	1995-05-30	Smithkline Beecham Corp.	TNF inhibitors
US5840496A (en)	1990-10-09	1998-11-24	Chiron Corporation	Method for diagnosing endometrial cancer
GB9022648D0 (en)	1990-10-18	1990-11-28	Charing Cross Sunley Research	Polypeptide and its use
US5858355A (en)	1990-12-20	1999-01-12	University Of Pittsburgh Of The Commonwealth System Of Higher Education	IRAP gene as treatment for arthritis
NZ241311A (en)	1991-01-17	1995-03-28	Gen Hospital Corp	Rna sequence having trans-splicing activity, plant strains
SG63617A1 (en)	1991-01-18	1999-03-30	Amgen Boulder Inc	Methods for treating tumar necrosis factor mediated diseases
ATE240740T1 (de)	1991-03-15	2003-06-15	Amgen Inc	Pegylation von polypeptiden
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
CA2121473C (en)	1991-10-15	2001-05-01	Michael Mullarkey	Methods and compositions for treating allergic reactions
US5961974A (en)	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
ES2038546B1 (es)	1991-11-08	1994-02-16	Andromaco Lab	Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
JPH07503132A (ja)	1991-12-17	1995-04-06	ジェンファーム　インターナショナル，インコーポレイティド	異種抗体を産生することができるトランスジェニック非ヒト動物
MX9300141A (es)	1992-01-13	1994-07-29	Smithkline Beecham Corp	Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JP2753395B2 (ja)	1992-03-04	1998-05-20	セル・セラピューティックス・インコーポレーテッド	鏡像異性体ヒドロキシル化キサンチン化合物
DE69333027T2 (de)	1992-03-30	2004-05-06	Immunex Corp., Seattle	Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
WO1993021946A1 (en)	1992-04-30	1993-11-11	Synergen, Inc.	Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
JPH05312248A (ja)	1992-05-08	1993-11-22	Nissan Motor Co Ltd	シフトレバー装置
DE4219626A1 (de)	1992-06-16	1993-12-23	Wehling Peter Priv Doz Dr Med	Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
JPH0630788A (ja)	1992-07-16	1994-02-08	Otsuka Pharmaceut Co Ltd	ヒトインターロイキン−１に対する組換え抗体
US5545716A (en)	1992-09-08	1996-08-13	University Of Florida	Superantigen agonist and antagonist peptides
ES2213744T3 (es)	1992-09-17	2004-09-01	Amgen Inc.	Composiciones farmaceuticas a base de inhibidores de la interleucina-1.
JPH06111399A (ja)	1992-09-30	1994-04-22	Sony Corp	光磁気記録媒体及びその製造方法
CA2146126A1 (en)	1992-10-07	1994-04-14	Kenji Irie	Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
US5891438A (en)	1992-10-30	1999-04-06	The Regents Of The University Of California	Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
US5866576A (en)	1992-12-16	1999-02-02	Cell Therapeutics, Inc.	Epoxide-containing compounds
ES2124801T3 (es)	1993-01-08	1999-02-16	Hoechst Ag	Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
DK0614984T4 (da)	1993-03-05	2010-12-20	Bayer Healthcare Llc	Humane monoklonale anti-TNF-alfa-antistoffer
CA2157782A1 (en)	1993-03-08	1994-09-15	Joseph C. Glorioso	Gene transfer for treating a connective tissue of a mammalian host
PT689449E (pt)	1993-03-19	2003-03-31	Vacsyn Sa	Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina
US6326353B1 (en)	1993-03-23	2001-12-04	Sequus Pharmaceuticals, Inc.	Enhanced circulation effector composition and method
US5843905A (en)	1993-06-04	1998-12-01	Vertex Pharmaceuticals, Incorporated	Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
FR2706772A1 (en)	1993-06-22	1994-12-30	Vacsyn Sa	Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
IL110492A0 (en)	1993-07-28	1994-10-21	Rhone Poulenc Rorer Ltd	(di(ether or thioether) heteroaryl or fluoro substituted aryl) compounds, their preparation and pharmaceutical compositions containing them
KR100340375B1 (ko)	1993-11-29	2002-11-13	메렐 파마슈티칼스 인크.	인터류킨-1활성억제제로서의신규한벤젠설포닐이민유도체
CA2138305A1 (en)	1993-12-28	1995-06-29	Naohito Ohashi	Tumor necrosis factor production inhibitors
GB9401460D0 (en)	1994-01-26	1994-03-23	Rhone Poulenc Rorer Ltd	Compositions of matter
US5608035A (en)	1994-02-02	1997-03-04	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
CA2183562A1 (en)	1994-02-18	1995-08-24	J. Peter Klein	Intracellular signalling mediators
CN1143363A (zh)	1994-03-09	1997-02-19	辉瑞大药厂	作为tnf释放抑制剂的异噁唑啉化合物
US5708142A (en)	1994-05-27	1998-01-13	Genentech, Inc.	Tumor necrosis factor receptor-associated factors
US5817822A (en)	1994-06-24	1998-10-06	Novartis Corporation	Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
IL114417A0 (en)	1994-07-07	1995-10-31	Res Dev Foundation	Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
US5877180A (en)	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
DE69519454T2 (de)	1994-07-14	2001-05-03	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama	Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US5641747A (en)	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
US5633227A (en)	1994-09-12	1997-05-27	Miles, Inc.	Secretory leukocyte protease inhibitor as an inhibitor of tryptase
IT1269989B (it)	1994-09-21	1997-04-16	Dompe Spa	Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
MX9702487A (es)	1994-10-05	1998-04-30	Darwin Discovery Ltd	Compuestos peptidilo y su uso terapeutico como inhibidores de las metaloproteasas.
US5852173A (en)	1994-10-19	1998-12-22	Genetics Institute, Inc.	TNF receptor death ligand proteins and inhibitors of ligand binding
TW464656B (en)	1994-11-15	2001-11-21	Hayashibara Biochem Lab	Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
ZA9510826B (en)	1994-12-23	1996-06-20	Smithkline Beecham Corp	3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
EP0796096A4 (en)	1994-12-23	1998-04-29	Smithkline Beecham Corp	4,4- (DISUBSTITUTED) CYCLOHEXAN-1-CARBOXYLATE MONOMERS AND RELATED COMPOUNDS
US6323201B1 (en)	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
KR19980701286A (ko)	1995-01-09	1998-05-15	오스카 아키히코	Tnf-알파 억제제
PE64396A1 (es)	1995-01-23	1997-01-28	Hoffmann La Roche	Proteina accesoria del receptor de la interleucina 1
AU710527B2 (en)	1995-02-23	1999-09-23	Novartis Nutrition Ag	Amino acid compositions and use thereof in clinical nutrition
WO1996028546A1 (en)	1995-03-15	1996-09-19	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
EP0737471A3 (fr)	1995-04-10	2000-12-06	L'oreal	Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
PT821671E (pt)	1995-04-20	2001-04-30	Pfizer	Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
US5981491A (en)	1995-05-10	1999-11-09	Darwin Discovery Limited	Peptidyl compounds and their therapeutic use
AR004471A1 (es)	1995-05-31	1998-12-16	Smithkline Beecham Corp	Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
US5817476A (en)	1995-06-07	1998-10-06	Genetics Institute, Inc.	Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5739143A (en)	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
US5830742A (en)	1995-06-08	1998-11-03	Immunex Corporation	TNF-α converting enzyme
ATE503013T1 (de)	1995-06-29	2011-04-15	Immunex Corp	Cytokin welches apoptose induziert
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
ZA966663B (en)	1995-08-17	1998-02-06	Genentech Inc	Traf Inhibitors.
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
WO1997008174A1 (en)	1995-08-31	1997-03-06	Smithkline Beecham Corporation	Interleukin converting enzyme and apoptosis
IL115245A (en)	1995-09-11	2002-12-01	Yissum Res Dev Co	Tumor necrosis factor inhibiting pharmaceuticals
US5968755A (en)	1995-09-27	1999-10-19	The Board Of Trustees Of The Leland Stanford Junior University	Methods for determining T-cell profiles of immunocompromised subjects
ATE229972T1 (de)	1995-10-05	2003-01-15	Darwin Discovery Ltd	Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
DE19540475A1 (de)	1995-10-20	1997-04-24	Schering Ag	Chirale Methylphenyloxazolidinone
US6281352B1 (en)	1995-11-14	2001-08-28	Dupont Pharmaceuticals Company	Macrocyclic compounds as metalloprotease inhibitors
EP0863885A2 (en)	1995-11-14	1998-09-16	The Du Pont Merck Pharmaceutical Company	Novel macrocyclic compounds as metalloprotease inhibitors
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
CO4750805A1 (es) *	1995-12-13	1999-03-31	Sumitomo Chemical Co	Compuesto para champu
US5869315A (en)	1995-12-18	1999-02-09	Basf Aktiengesellschaft	Modified interleukin-1β converting enzyme with increased stability
US5990119A (en)	1995-12-21	1999-11-23	Smithkline Beecham Corporation	1,4,4-(trisubstituted)cyclohexane monomers and related compounds
US5869677A (en)	1995-12-21	1999-02-09	Smithkline Beecham Corporation	3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
US5891883A (en)	1995-12-21	1999-04-06	Smithkline Beecham Corporation	4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6613544B1 (en) *	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
CA2238885A1 (en)	1995-12-29	1997-07-10	Incyte Pharmaceuticals, Inc.	Nucleic acids encoding interferon gamma inducing factor-2
US6046048A (en)	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
ATE239041T1 (de)	1996-02-09	2003-05-15	Basf Ag	Humane antikörper welche an humanen tnfalpha binden
CA2244664C (en)	1996-02-09	2008-06-03	Amgen Inc.	Composition comprising interleukin-1 inhibitor and controlled release polymer
US5994351A (en)	1998-07-27	1999-11-30	Pfizer Inc.	Arylsulfonylamino hydroxamic acid derivatives
US5981220A (en)	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
GB9607119D0 (en)	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
GB9607120D0 (en)	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
GB9607249D0 (en)	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
US5710013A (en)	1996-04-19	1998-01-20	Tularik Inc.	Tumor necrosis factor receptor associated factor 6 (TRAF6)
GB9609795D0 (en)	1996-05-10	1996-07-17	Smithkline Beecham Plc	Novel compounds
AUPO048296A0 (en)	1996-06-14	1996-07-11	Fujisawa Pharmaceutical Co., Ltd.	New compound and its preparation
US6060283A (en)	1996-06-27	2000-05-09	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
EP0818439B1 (en)	1996-07-02	1999-10-13	Nisshin Flour Milling Co., Ltd.	Imide derivatives
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH10130149A (ja)	1996-07-12	1998-05-19	Sankyo Co Ltd	Ｔｎｆ産生抑制剤
US5853977A (en)	1996-07-12	1998-12-29	Schering Corporation	Mammalian TNF-α convertases
US5877222A (en)	1996-07-19	1999-03-02	The Regents Of The University Of California	Method for treating aids-associated dementia
GB9616643D0 (en)	1996-08-08	1996-09-25	Chiroscience Ltd	Compounds
HUP9904569A3 (en)	1996-08-12	2001-11-28	Celgene Corp Warren	Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US6069132A (en)	1996-08-14	2000-05-30	Revanker; Ganapathi R.	Phosphazole compounds
ES2217428T3 (es)	1996-09-25	2004-11-01	Ss Pharmaceutical Co., Ltd.	Derivados de vinilpiridina sustituidos y medicamentos que los contienen.
US5962481A (en)	1996-10-16	1999-10-05	American Cyanamid Company	Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB9621859D0 (en)	1996-10-21	1996-12-11	Xenova Ltd	Cytokine production inhibitors
GB9712761D0 (en)	1997-06-17	1997-08-20	Chiroscience Ltd	Quinolines and their therapeutic use
JPH10147531A (ja)	1996-11-19	1998-06-02	Otsuka Pharmaceut Co Ltd	ＴＮＦ−α産生抑制剤
US5955480A (en)	1996-11-20	1999-09-21	Merck & Co., Inc.	Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JP2001504490A (ja)	1996-11-20	2001-04-03	メルクエンドカンパニーインコーポレーテッド	トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法
US5834435A (en)	1996-11-27	1998-11-10	Slesarev; Vladimir I.	Inhibition of TNF-α pleiotropic and cytotoxic effects
EP1972194A1 (en)	1996-12-03	2008-09-24	Amgen Fremont Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
CA2273850A1 (en)	1996-12-06	1998-06-11	Amgen Inc.	Combination therapy using a tnf binding protein for treating tnf-mediated diseases
DE19652227A1 (de)	1996-12-16	1998-06-18	Bosch Gmbh Robert	Verfahren und Vorrichtung zum Zuordnen einer Fernbedienung zu einer Basisstation
JPH10231285A (ja)	1996-12-17	1998-09-02	Ishihara Sangyo Kaisha Ltd	フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物
EP2371962A3 (en)	1996-12-23	2011-12-21	Immunex Corporation	Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
US7141393B2 (en)	1996-12-26	2006-11-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18-receptor proteins
PT853083E (pt)	1997-01-06	2001-12-28	Pfizer	Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US5952320A (en)	1997-01-07	1999-09-14	Abbott Laboratories	Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en)	1997-01-07	1998-07-02	Abbott Lab	C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US6054559A (en)	1997-01-28	2000-04-25	Smithkline Beecham Corporation	Interleukin-1 receptor antagonist beta (IL-1raβ)
CA2279186C (en)	1997-01-29	2004-02-24	Pfizer Inc.	Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
JP3955352B2 (ja) *	1997-02-25	2007-08-08	株式会社林原生物化学研究所	破骨細胞形成阻害剤
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6476027B1 (en)	1997-03-04	2002-11-05	Monsanto Company	N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en)	1997-03-04	1998-09-11	Monsanto Company	Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6362183B1 (en)	1997-03-04	2002-03-26	G. D. Searle & Company	Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6380258B2 (en)	1997-03-04	2002-04-30	G. D. Searle, L.L.C.	Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
CA2285405A1 (en)	1997-03-04	1998-09-11	Monsanto Company	Amidoaromatic ring sulfonamide hydroxamic acid compounds
US6087116A (en)	1997-03-12	2000-07-11	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18 (IL-18) receptor polypeptides and their uses
US6054487A (en)	1997-03-18	2000-04-25	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
JPH10259140A (ja)	1997-03-18	1998-09-29	Sumitomo Pharmaceut Co Ltd	腫瘍壊死因子産生抑制剤
BR9810409A (pt)	1997-03-18	2000-08-22	Basf Ag	Métodos e composições para a modulação de responsividade a corticosteróides
AU6769298A (en)	1997-03-21	1998-10-20	Cistron Biotechnology, Inc.	Method for inhibiting cleavage of precursor il-1beta
GB9706255D0 (en)	1997-03-26	1997-05-14	Smithkline Beecham Plc	Novel compounds
WO1998043946A1 (en)	1997-03-28	1998-10-08	Zeneca Limited	Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
JP2001518090A (ja)	1997-03-28	2001-10-09	ゼネカリミテッド	腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸
HUP0001243A3 (en)	1997-04-04	2000-10-30	Pfizer Prod Inc	Nicotinamide derivatives and pharmaceutical compositions containing them
US6117654A (en)	1997-08-04	2000-09-12	Millennium Biotherapeutics, Inc.	Nucleic acid molecules encoding Tango-77-polypeptides
NZ500712A (en)	1997-04-10	2002-10-25	Agennix Inc	Use of a lactoferin product to inhibit the inflammatory activity of interleukin-1 beta in the treatment of allergen-induced inflammatory disorders
ES2263204T5 (es)	1997-04-15	2013-10-14	Daiichi Sankyo Company, Limited	Nueva proteína y proceso para producir la misma
US5843678A (en) *	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CN1264427A (zh) *	1997-04-16	2000-08-23	安姆根有限公司	osteoprotegerin结合蛋白和受体
FR2762315B1 (fr)	1997-04-22	1999-05-28	Logeais Labor Jacques	Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
BR9808998A (pt)	1997-04-24	2000-08-08	Ortho Mcneil Pharm Inc	Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
FR2762514B1 (fr)	1997-04-29	1999-10-22	Sanofi Sa	Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
JP3776203B2 (ja)	1997-05-13	2006-05-17	第一製薬株式会社	Ｉｃａｍ−１産生阻害剤
PL336990A1 (en)	1997-05-22	2000-07-31	Searle & Co	3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
US6265535B1 (en)	1997-05-30	2001-07-24	The Trustees Of The University Of Pennsylvania	Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
JPH111481A (ja)	1997-06-10	1999-01-06	Sumitomo Pharmaceut Co Ltd	ピペリジニルフタラジン誘導体
HUP0003309A3 (en)	1997-06-12	2002-02-28	Rhone Poulenc Rorer Ltd West M	Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same
KR19990001101A (ko)	1997-06-12	1999-01-15	손경식	캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물
WO1998056377A1 (en)	1997-06-13	1998-12-17	Smithkline Beecham Corporation	Novel pyrazole and pyrazoline substituted compounds
GB9713733D0 (en)	1997-06-27	1997-09-03	Pharmacia & Upjohn Spa	Poly-branched polycarboxamido compounds
GB9713732D0 (en)	1997-06-27	1997-09-03	Pharmacia & Upjohn Spa	Substituted triazinic compounds
US6235787B1 (en)	1997-06-30	2001-05-22	Hoffmann-La Roche Inc.	Hydrazine derivatives
GB9713726D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
US6040320A (en)	1997-06-30	2000-03-21	Ortho-Mcneil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
AU8280798A (en)	1997-07-03	1999-01-25	Thomas Jefferson University	An improved method for design and selection of efficacious antisense oligonucleotides
US5843721A (en)	1997-07-03	1998-12-01	Tularik Inc.	Nucleic acids encoding human NIK protein
JP2001500533A (ja)	1997-07-10	2001-01-16	フアルマシア・エ・アツプジヨン・エツセ・ピー・アー	マトリックスメタロプロテイナーゼ・インヒビター
DE19731521A1 (de)	1997-07-23	1999-01-28	Byk Gulden Lomberg Chem Fab	Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems
FR2766822B1 (fr)	1997-07-30	2001-02-23	Adir	Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR016551A1 (es)	1997-07-30	2001-07-25	Smithkline Beecham Corp	Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
CA2295295A1 (en)	1997-07-31	1999-02-11	Celgene Corporation	Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels
WO1999006410A1 (en)	1997-08-04	1999-02-11	Amgen Inc.	Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
HUP0001054A3 (en)	1997-08-06	2001-01-29	Daiichi Asubio Pharma Co Ltd	1-aryl-1,8-naphthyridin-4-one derivative as type iv phosphodiesterase inhibitor
WO1999007679A1 (en)	1997-08-08	1999-02-18	Chiroscience Limited	Peptidyl compounds having mmp and tnf inhibitory activity
DE69805473T2 (de)	1997-08-08	2003-01-16	Pfizer Products Inc., Groton	Arylsulfonylaminohydroxamsäurederivate
IL121860A0 (en)	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
US5994396A (en)	1997-08-18	1999-11-30	Centaur Pharmaceuticals, Inc.	Furansulfonic acid derivatives and pharmaceutical compositions containing the same
WO1999009965A2 (en)	1997-08-21	1999-03-04	Takeda Chemical Industries, Ltd.	Anti-inflammatory agent
JP2001521906A (ja)	1997-11-03	2001-11-13	ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー	血管新生を阻害し、癌を処置するための方法及び組成物
US5955476A (en)	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
WO1999029865A2 (en)	1997-12-12	1999-06-17	The Rockefeller University	A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
EP1047683A1 (en)	1998-01-16	2000-11-02	Centaur Pharmaceuticals, Inc.	Thioether furan nitrone compounds
DE69811404T2 (de)	1998-01-20	2003-12-04	Abbott Gmbh & Co. Kg	N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-flurophenyl)1,6-dihydro-1-pyrimidinyl)acetoxyl)-l-asparaginsäure aldehyde als in vivo inhibitor des interleukin-1beta konvertierenden enzyms
ATE301195T1 (de)	1998-01-23	2005-08-15	Immunex Corp	Acpl dna und polypeptide
ES2226335T3 (es)	1998-01-23	2005-03-16	Immunex Corporation	Receooctires de uk.18.
JP2002528046A (ja)	1998-01-27	2002-09-03	ミレニアム・フアーマシユーチカルズ・インコーポレーテツド	新規レセプタースーパーファミリー分子およびそれについての用途
KR20010034406A (ko)	1998-01-27	2001-04-25	아메리칸 사이아나미드 컴파니	매트릭스 메탈로프로테인아제 억제제로서의2,3,4,5-테트라하이드로-1ｈ-[1,4]-벤조디아제핀-3-하이드록삼산
DE69925581T2 (de)	1998-03-09	2006-04-27	Vertex Pharmaceuticals Inc., Cambridge	1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
CN1297354A (zh)	1998-03-16	2001-05-30	西托维亚公司	二肽卡斯帕酶抑制剂及其用途
CA2324226C (en)	1998-03-19	2012-06-05	Vertex Pharmaceuticals Incorporated	Inhibitors of caspases
IL126024A0 (en)	1998-03-19	1999-05-09	Yeda Res & Dev	Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
DE69929877T2 (de)	1998-03-20	2006-08-10	Daiichi Asubio Pharma Co., Ltd.	BENZOCHINONDERIVATE ENTHALTENDE HEMMER VON NF-kB
CN1305846C (zh)	1998-03-26	2007-03-21	参天制药株式会社	脲衍生物
AU762574B2 (en)	1998-05-14	2003-06-26	Immunex Corporation	Method of inhibiting osteoclast activity
CA2276216A1 (en)	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
KR100537558B1 (ko)	1998-09-01	2005-12-19	가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조	인터류킨-18 결합 단백질
ATE291628T1 (de) *	1998-09-15	2005-04-15	Pharmexa As	Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
DK2112166T3 (en) *	1998-12-23	2019-02-04	Pfizer	Human monoclonal antibodies to CTLA-4
PT1149114E (pt)	1999-02-03	2014-05-22	Amgen Inc	Polipéptidos envolvidos na resposta imunitária
WO2000047740A2 (en)	1999-02-12	2000-08-17	Amgen Inc.	Tnf-related proteins
AUPQ314799A0 (en)	1999-09-29	1999-10-21	University Of Western Australia, The	Bone cell factor
AR026946A1 (es)	1999-12-16	2003-03-05	Amgen Inc	Osteoprotegerina/receptores de factores de necrosis de tumores
DE60134459D1 (de) †	2000-02-23	2008-07-31	Amgen Inc	Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
WO2001083525A2 (en)	2000-05-03	2001-11-08	Amgen Inc.	Modified peptides, comprising an fc domain, as therapeutic agents
US7102050B1 (en)	2000-05-04	2006-09-05	Exxonmobil Chemical Patents Inc.	Multiple riser reactor
US20030215450A1 (en) *	2000-05-26	2003-11-20	Blake Simon M	Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US7405734B2 (en) *	2000-07-18	2008-07-29	Silicon Graphics, Inc.	Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units
DE10039710B4 (de)	2000-08-14	2017-06-22	United Monolithic Semiconductors Gmbh	Verfahren zur Herstellung passiver Bauelemente auf einem Halbleitersubstrat
WO2002016551A2 (en) *	2000-08-18	2002-02-28	University Of Massachusetts Medical Center	Trance regulation of chondrocyte differentiation
EP1458411A2 (en)	2000-08-21	2004-09-22	Smithkline Beecham Corporation	Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
IL156661A0 (en) *	2001-01-05	2004-01-04	Pfizer	Antibodies to insulin-like growth factor i receptor
EP1399175A4 (en)	2001-05-17	2005-11-30	Immunex Corp	THERAPEUTIC USE OF RANK ANTAGONISTS
EP1432438A2 (en)	2001-06-06	2004-06-30	Immunex Corporation	Use of rank antagonists to treat cancer
JP4212470B2 (ja)	2001-06-26	2009-01-21	アムジェンフレモントインク．	Ｏｐｇｌへの抗体
AU2003243139B2 (en) *	2002-04-05	2007-06-21	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2013180295A1 (ja)	2012-06-01	2013-12-05	日本電信電話株式会社	パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof

2002
- 2002-06-25 JP JP2003509075A patent/JP4212470B2/ja not_active Expired - Lifetime
- 2002-06-25 SG SG2011076551A patent/SG2011076551A/en unknown
- 2002-06-25 TR TR2018/09678T patent/TR201809678T4/tr unknown
- 2002-06-25 BR BR0210579-9 patent/BRPI0210579B8/pt not_active IP Right Cessation
- 2002-06-25 EP EP10181323.6A patent/EP2270052B8/en not_active Expired - Lifetime
- 2002-06-25 ES ES10185344T patent/ES2706902T3/es not_active Expired - Lifetime
- 2002-06-25 PT PT10185344T patent/PT2295081T/pt unknown
- 2002-06-25 DE DE122010000047C patent/DE122010000047I1/de active Pending
- 2002-06-25 PH PH1/2012/502439A patent/PH12012502439A1/en unknown
- 2002-06-25 PL PL371915A patent/PL222211B1/pl unknown
- 2002-06-25 DK DK09156995.4T patent/DK2087908T3/en active
- 2002-06-25 EP EP02749660.3A patent/EP1409016B9/en not_active Expired - Lifetime
- 2002-06-25 RS RS20120347A patent/RS54274B1/en unknown
- 2002-06-25 CA CA2451955A patent/CA2451955C/en not_active Expired - Lifetime
- 2002-06-25 DK DK02749660.3T patent/DK1409016T4/da active
- 2002-06-25 PT PT101813236T patent/PT2270052T/pt unknown
- 2002-06-25 SG SG10201603108QA patent/SG10201603108QA/en unknown
- 2002-06-25 ES ES02749660T patent/ES2342820T5/es not_active Expired - Lifetime
- 2002-06-25 PT PT91569954T patent/PT2087908T/pt unknown
- 2002-06-25 CN CN201310052370.5A patent/CN103232539B/zh not_active Expired - Lifetime
- 2002-06-25 EP EP10185344.8A patent/EP2295081B1/en not_active Expired - Lifetime
- 2002-06-25 AU AU2002320157A patent/AU2002320157C1/en active Active
- 2002-06-25 NZ NZ530765A patent/NZ530765A/en not_active IP Right Cessation
- 2002-06-25 EA EA200400063A patent/EA021242B9/ru active Protection Beyond IP Right Term
- 2002-06-25 NZ NZ616594A patent/NZ616594A/en not_active IP Right Cessation
- 2002-06-25 ME MEP-326/08A patent/MEP32608A/xx unknown
- 2002-06-25 IL IL15951202A patent/IL159512A0/xx unknown
- 2002-06-25 KR KR1020107002067A patent/KR101038585B1/ko active Protection Beyond IP Right Term
- 2002-06-25 ES ES09156995.4T patent/ES2675735T3/es not_active Expired - Lifetime
- 2002-06-25 PT PT02749660T patent/PT1409016E/pt unknown
- 2002-06-25 EP EP09156995.4A patent/EP2087908B1/en not_active Expired - Lifetime
- 2002-06-25 YU YU103003A patent/YU103003A/sh unknown
- 2002-06-25 EP EP18202340.8A patent/EP3492100B1/en not_active Expired - Lifetime
- 2002-06-25 MX MXPA04000134A patent/MXPA04000134A/es active IP Right Grant
- 2002-06-25 TR TR2018/09008T patent/TR201809008T4/tr unknown
- 2002-06-25 PH PH1/2012/502440A patent/PH12012502440A1/en unknown
- 2002-06-25 TR TR2019/00581T patent/TR201900581T4/tr unknown
- 2002-06-25 ES ES18202340T patent/ES2907826T3/es not_active Expired - Lifetime
- 2002-06-25 DE DE60235989T patent/DE60235989D1/de not_active Expired - Lifetime
- 2002-06-25 DK DK10181323.6T patent/DK2270052T3/en active
- 2002-06-25 NZ NZ547695A patent/NZ547695A/en not_active IP Right Cessation
- 2002-06-25 KR KR10-2003-7017009A patent/KR20040023630A/ko active Search and Examination
- 2002-06-25 US US10/180,648 patent/US7364736B2/en not_active Expired - Lifetime
- 2002-06-25 NO NO20200535A patent/NO345566B1/no not_active IP Right Cessation
- 2002-06-25 CN CNA028166809A patent/CN1547486A/zh active Pending
- 2002-06-25 ES ES10181323.6T patent/ES2674888T3/es not_active Expired - Lifetime
- 2002-06-25 AT AT02749660T patent/ATE464068T1/de active
- 2002-06-25 DK DK10185344.8T patent/DK2295081T3/en active
- 2002-06-25 SG SG2005081195A patent/SG173211A1/en unknown
- 2002-06-25 WO PCT/US2002/020181 patent/WO2003002713A2/en active Application Filing
- 2002-06-25 MY MYPI20022368A patent/MY143582A/en unknown
- 2002-06-25 ME MEP-2008-326A patent/ME00232B/me unknown
- 2002-06-26 AR ARP020102401A patent/AR034637A1/es active IP Right Grant
- 2002-06-26 TW TW091114055A patent/TWI276443B/zh not_active IP Right Cessation
- 2002-06-26 TW TW095103780A patent/TWI326285B/zh not_active IP Right Cessation
2003
- 2003-12-22 IL IL159512A patent/IL159512A/en active IP Right Grant
2004
- 2004-01-23 ZA ZA200400521A patent/ZA200400521B/xx unknown
- 2004-03-10 NO NO20041018A patent/NO343687B1/no not_active IP Right Cessation
2005
- 2005-06-25 NZ NZ581637A patent/NZ581637A/en not_active IP Right Cessation
2007
- 2007-10-30 US US11/981,664 patent/US8058418B2/en not_active Expired - Lifetime
2008
- 2008-07-04 JP JP2008175541A patent/JP4358282B2/ja not_active Expired - Lifetime
- 2008-12-19 AU AU2008261137A patent/AU2008261137C1/en active Active
2009
- 2009-07-08 JP JP2009161406A patent/JP4927910B2/ja not_active Expired - Lifetime
2010
- 2010-07-08 CY CY20101100637T patent/CY1110196T1/el unknown
- 2010-11-24 CY CY2010016C patent/CY2010016I1/el unknown
- 2010-11-24 LU LU91757C patent/LU91757I2/fr unknown
- 2010-11-25 FR FR10C0050C patent/FR10C0050I2/fr active Active
2011
- 2011-11-14 US US13/296,201 patent/US8409578B2/en not_active Expired - Lifetime
2012
- 2012-01-17 JP JP2012006740A patent/JP5065529B2/ja not_active Expired - Lifetime
- 2012-03-23 JP JP2012066632A patent/JP2012153701A/ja not_active Withdrawn
- 2012-07-02 JP JP2012148656A patent/JP5576903B2/ja not_active Expired - Lifetime
2013
- 2013-03-14 US US13/831,099 patent/US20140134157A1/en not_active Abandoned
2014
- 2014-02-05 HK HK14101098.3A patent/HK1187932A1/xx not_active IP Right Cessation
- 2014-10-19 IL IL235116A patent/IL235116A0/en unknown
- 2014-10-28 JP JP2014218929A patent/JP2015057408A/ja active Pending
- 2014-11-27 JP JP2014239576A patent/JP2015078205A/ja active Pending
2015
- 2015-02-12 US US14/621,072 patent/US20150266952A1/en not_active Abandoned
2016
- 2016-06-07 JP JP2016113389A patent/JP2016216464A/ja active Pending
- 2016-09-02 US US15/256,194 patent/US20170183417A1/en not_active Abandoned
2017
- 2017-12-25 JP JP2017247287A patent/JP2018154614A/ja not_active Ceased
2018
- 2018-06-26 CY CY181100655T patent/CY1120656T1/el unknown
- 2018-07-17 CY CY181100747T patent/CY1120658T1/el unknown
2019
- 2019-01-21 CY CY20191100079T patent/CY1121151T1/el unknown
- 2019-04-04 NO NO20190456A patent/NO344842B1/no not_active IP Right Cessation
- 2019-06-10 JP JP2019107837A patent/JP2019214563A/ja active Pending
- 2019-11-05 NO NO2019039C patent/NO2019039I1/no unknown
- 2019-12-20 NO NO2019048C patent/NO2019048I1/no unknown
- 2019-12-24 JP JP2019232389A patent/JP2020073518A/ja active Pending
2020
- 2020-01-09 US US16/738,751 patent/US20200131271A1/en not_active Abandoned
- 2020-06-18 US US16/905,089 patent/US20200354464A1/en not_active Abandoned
2021
- 2021-08-05 JP JP2021128771A patent/JP2022000424A/ja active Pending

Also Published As

Publication number	Publication date
JP2012140430A (ja)	2012-07-26
ES2342820T5 (es)	2021-04-14
YU103003A (sh)	2006-05-25
IL159512A (en)	2014-12-31
CA2451955C (en)	2015-09-29
TWI326285B (en)	2010-06-21
ES2706902T3 (es)	2019-04-01
TR201809008T4 (tr)	2018-07-23
BRPI0210579B1 (pt)	2019-05-14
LU91757I2 (fr)	2011-01-24
JP2022000424A (ja)	2022-01-04
CY1120656T1 (el)	2019-12-11
ES2675735T3 (es)	2018-07-12
EA021242B1 (ru)	2015-05-29
CY1110196T1 (el)	2012-01-25
EP3492100B1 (en)	2021-12-08
NO2019039I1 (no)	2019-11-05
CY2010016I2 (el)	2012-01-25
CN103232539A (zh)	2013-08-07
SG173211A1 (en)	2011-08-29
NO345566B1 (no)	2021-04-19
JP2020073518A (ja)	2020-05-14
EP2295081B1 (en)	2018-10-31
AU2008261137A1 (en)	2009-01-15
EP2270052B1 (en)	2018-03-28
RS20120347A3 (en)	2013-10-31
NO20041018L (no)	2004-03-10
BRPI0210579B8 (pt)	2021-05-25
FR10C0050I2 (fr)	2011-12-30
DE122010000047I1 (de)	2011-05-05
US7364736B2 (en)	2008-04-29
PT2270052T (pt)	2018-07-04
US20090274688A1 (en)	2009-11-05
JP2016216464A (ja)	2016-12-22
EP2087908A1 (en)	2009-08-12
HK1187932A1 (zh)	2014-04-17
EP2270052A3 (en)	2011-03-02
US20040033535A1 (en)	2004-02-19
KR101038585B1 (ko)	2011-06-03
PT2087908T (pt)	2018-07-16
PT1409016E (pt)	2010-06-11
ES2674888T3 (es)	2018-07-04
KR20040023630A (ko)	2004-03-18
NO2019048I1 (no)	2019-12-20
MEP32608A (hr)	2011-02-10
TR201809678T4 (tr)	2018-07-23
JP2009273466A (ja)	2009-11-26
ME00232B (me)	2011-02-10
US8409578B2 (en)	2013-04-02
NZ530765A (en)	2006-11-30
DK2295081T3 (en)	2019-02-18
US20120087923A1 (en)	2012-04-12
US20200131271A1 (en)	2020-04-30
JP2018154614A (ja)	2018-10-04
JP2015057408A (ja)	2015-03-26
ATE464068T1 (de)	2010-04-15
JP5065529B2 (ja)	2012-11-07
WO2003002713A3 (en)	2003-08-14
JP2009022280A (ja)	2009-02-05
EP1409016A4 (en)	2005-11-09
RS54274B1 (en)	2016-02-29
TWI276443B (en)	2007-03-21
MXPA04000134A (es)	2005-06-06
EP3492100A1 (en)	2019-06-05
EP2295081A1 (en)	2011-03-16
FR10C0050I1 (ja)	2011-01-14
JP4927910B2 (ja)	2012-05-09
JP2015078205A (ja)	2015-04-23
CN103232539B (zh)	2015-06-03
EP2270052B8 (en)	2018-05-02
PT2295081T (pt)	2019-02-01
IL159512A0 (en)	2004-06-01
DK2270052T3 (en)	2018-07-02
JP2012153701A (ja)	2012-08-16
US8058418B2 (en)	2011-11-15
DK1409016T3 (da)	2010-06-21
NO343687B1 (no)	2019-05-06
NO344842B1 (no)	2020-05-25
ES2907826T3 (es)	2022-04-26
PH12012502440A1 (en)	2013-06-17
TW200630107A (en)	2006-09-01
DE60235989D1 (de)	2010-05-27
TR201900581T4 (tr)	2019-02-21
JP5576903B2 (ja)	2014-08-20
EP1409016B1 (en)	2010-04-14
KR20100041797A (ko)	2010-04-22
AU2008261137C1 (en)	2023-08-31
EP2087908B1 (en)	2018-05-30
EP1409016B2 (en)	2020-07-15
WO2003002713A2 (en)	2003-01-09
US20200354464A1 (en)	2020-11-12
NO20200535A1 (no)	2004-03-10
IL235116A0 (en)	2014-11-30
EP2270052A2 (en)	2011-01-05
US20150266952A1 (en)	2015-09-24
PL222211B1 (pl)	2016-07-29
CY2010016I1 (el)	2012-01-25
EA200400063A1 (ru)	2005-02-24
JP2005506963A (ja)	2005-03-10
EP1409016B9 (en)	2020-10-28
RS20120347A2 (en)	2013-04-30
CY1121151T1 (el)	2020-05-29
CA2451955A1 (en)	2003-01-09
DK1409016T4 (da)	2020-09-14
JP4212470B2 (ja)	2009-01-21
NZ581637A (en)	2012-05-25
AU2002320157C1 (en)	2023-09-21
US20170183417A1 (en)	2017-06-29
SG10201603108QA (en)	2016-05-30
PH12012502439A1 (en)	2013-06-17
BR0210579A (pt)	2005-05-10
MY143582A (en)	2011-05-31
NZ616594A (en)	2015-06-26
DK2087908T3 (en)	2018-07-23
AR034637A1 (es)	2004-03-03
JP2019214563A (ja)	2019-12-19
SG2011076551A (en)	2015-08-28
EA021242B9 (ru)	2015-11-30
EP1409016A2 (en)	2004-04-21
PL371915A1 (en)	2005-07-11
CN1547486A (zh)	2004-11-17
US20140134157A1 (en)	2014-05-15
LU91757I9 (ja)	2019-01-03
JP4358282B2 (ja)	2009-11-04
NO20190456A1 (no)	2004-03-10
AU2002320157B2 (en)	2008-10-16
CY1120658T1 (el)	2019-12-11
JP2012229236A (ja)	2012-11-22
NZ547695A (en)	2008-09-26
ES2342820T3 (es)	2010-07-15
AU2008261137B2 (en)	2012-10-04

Publication	Publication Date	Title
ZA200400521B (en)	2005-07-27	Antibodies to OPGL.
AP2004003034A0 (en)	2004-06-30	Antibodies to CD40.
MXPA03009390A (es)	2004-01-29	Anticuerpos para integrina vla-1.
EP1432444A4 (en)	2005-11-02	ANTI-BETA ANTIBODIES
HK1074206A1 (en)	2005-11-04	Anti-trail-r antibodies
MXPA03001590A (es)	2003-06-04	Anticuerpos para la il-1beta humana.
GB0118651D0 (en)	2001-09-19	Flat-plate
ZA200208561B (en)	2003-05-19	Hydraulischer druckverstarker.
MXPA01009037A (es)	2003-11-18	I-bet.
AU2002365649A8 (en)	2003-06-17	Anti-dota antibody
MXPA03007915A (es)	2003-12-04	Vacuna.
GB0126378D0 (en)	2002-01-02	Antigen
MXPA03005286A (es)	2003-10-06	METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008139A (es)	2003-12-12	Fluoralcoxifenilsulfonilureas sustituidas.
ZA200204985B (en)	2003-02-20	Activated rec-D-hydantoinases.
AU2002231806A1 (en)	2002-09-04	H. influenzae antigen basb213
GB0119553D0 (en)	2001-10-03	Antibodies
ZA200108074B (en)	2003-09-30	Structure.
GB0119004D0 (en)	2001-09-26	Antibody
GB0123599D0 (en)	2001-11-21	Recilless I.C. engine
ZA200300001B (en)	2003-08-04	Improvements to platsol process.
AP2001000098S (en)	2003-06-06	Marimbira.
MXPA01005710A (es)	2003-08-20	Losa-cimbra.
MXPA01005709A (es)	2003-09-10	Panel-cimbra.
GB0119932D0 (en)	2001-10-10	G.l.g.